Injectable treatment for congenital factor VII deficiency
Treatments studied
Part of Blood & lymphatic, Genetic & congenital clinical trials.
This study tests an investigational injection called SR604 (given under the skin) to see if it can safely and effectively prevent and treat bleeding episodes in people with congenital factor VII deficiency, a rare condition that makes blood clotting hard. It is a phase 2 trial, meaning the drug is still being studied for its effects and safety.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 12 and 65 years old.
- You need a confirmed diagnosis of congenital factor VII deficiency with factor VII activity below 10%.
- You must have had at least 2 treated bleeding episodes in the last 3 months.
- You cannot have active bleeding before starting the study drug.
- You must agree to use reliable birth control during the study if you are of childbearing age.
- You cannot have other bleeding disorders, blood clots, or certain medical conditions like severe heart disease or HIV.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-stage trial tests a new injectable medicine called SR604 designed to help people with hemophilia A, hemophilia B, or congenital Factor VII deficiency—conditions where the blood doesn't clot properly. The study will look at how safe the medicine is and whether it reduces bleeding episodes.
This study tests a new drug called SR604 to see if it is safe and how it works in the body. It is for healthy men and for people with hemophilia A, hemophilia B, or factor VII deficiency who have frequent bleeding or are on preventive treatment.
This study tests whether KN057, a new preventive medicine, is safe for males with hemophilia A or B. It aims to help prevent bleeding episodes without causing unwanted blood clots.
This early-phase study tests an FVIII gene therapy to help your body make more of the missing clotting factor in hemophilia A. It’s aimed at adults with severe low FVIII levels who have already used FVIII replacement products for a long time and have not developed an immune blocker (an inhibitor).
This study tests a new medicine called SCT800 for boys with severe hemophilia A who have never been treated with factor VIII before. The goal is to see if it works safely to prevent bleeding.
This trial tests a gene therapy to help your body produce more of the clotting protein (factor VIII) it's missing. It may reduce or stop the need for regular factor infusions.
Hear when a new Factor VII Deficiency trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.